A protocol for a multi-centre, double-blinded, randomised, placebo-controlled trial on the efficacy and safety of lopinavir/ ritonavir plus ribavirin in the treatment of severe acute respiratory syndrome (SARS) was produced. It can be referred to or modified should a future outbreak of SARS occur in Hong Kong.